M
Meditrina
Developed the Aveta™ sterile, single-use resecting hysteroscope for physicians
About Meditrina
Meditrina is a medical device company focused on women's healthcare, specifically in the field of gynecology. The company has developed the Aveta System, a platform for diagnostic and therapeutic hysteroscopy procedures to address various intrauterine pathologies, such as polyps and fibroids. The system is designed as a "see and treat" solution, enabling physicians to both visualize and remove tissue within the uterus in a single procedure.
The Aveta System consists of a single-use resecting hysteroscope with high-definition vision, which provides a clear view of the uterine cavity. A key feature of the system is its small insertion diameter, which is intended to enhance patient comfort. The device also incorporates an expandable working channel, allowing for the use of instruments for tissue removal. The business model likely revolves around the sale of the Aveta System and the disposable components, such as the single-use hysteroscopes, to hospitals and clinics. The target market includes gynecologists and other healthcare providers who perform hysteroscopies. By offering a minimally invasive solution, Meditrina aims to improve the standard of care for women with uterine conditions.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2020 | $10M | $40M | Deerfield | — |
| EARLY VC✓Equity / VC | Oct 2019 | $13M | $52M | ShangBay Capital · Alumni Ventures | — |
Growth signals
Latest recorded traffic for Meditrina is 3.8K monthly website visits, up 475.8% over the last three months. Meditrina's team grew 5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
ShangBay Capital
Alumni Ventures
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Meditrina on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Meditrina’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.